• References


    • Pharmaceuticals: Healthcare


References

Amberlite IRP64 Application Reference List

  • Controlled/Sustained Release
    Leo Corporation, 1973. Smoking substitutes and method of production. Patent GB 1,325,011.
  • Taste-Masking
    Douglas, S.J. Glaxo Group Research Ltd, 1990. Process for the preparation of a ranitidine resin absorbate. US5219563.
  • Astruc, J., and A. Sambot, 1970. Ion-exchange resin: spiramycin compositions. Patent GB 1,180,233.
  • Borodkin, S., and D.P. Sundberg, 1971. Chewable tablets including coated particles of psuedo-ephedine-weak cation exchange resin. Patent US 3,594,470.
  • Other
  • Fretland, D.J., 1974. Use of ion-exchange resins for removing prostaglandins from human urine prior to radioimunoassay. Prostaglandins 6 (5): 421-425.
  • Miles Laboratories, Inc., 1970, Detection device for enzymes and other factors in body fluids.
    Patent US 3,616,251.

 

Amberlite IRP69 Application Reference List

Modified Release

  • Amsel, L.P., O.N. Hinsvark, K. Rotenberg, and J.L. Sheumaker, 1983. recent advances in sustained release technology utilizing ion exchange polymers. Proc. Pharm Tech. Conf. '83: 251-266.
  • Ferro, M.T., and F.C. Mondelo, 1987. Preparation of (-) eburnamenin-1,4(1,5H)-one resinates. Patent GB2,184,731.Raghunathan, Y., 1980. Prolonged release pharmaceutical preparations. Patent US 4,221,778.
  • Raghunathan, Y., L.P. Amsel, O.N. Hinsvark, and W. Bryant, 1981. Sustained-release drug delivery system I: Coated ion exchange resin system for phenylpropanolamine and other drugs.
  • J. Phar. Sci. 70 (4): 379-384.Raghunathan, Y., 1983. Sustained-release liquid pharmaceuticals containing ionic components. Patent US 532,864.
  • Raghunathan, Y., 1989. Controlled release pharmaceutical preparations. Patent US 4,487,077.
  • Sheumaker, J.L, 1988. Liquid prolonged release pharmaceutical formulations containing ionic constituents. Patent US 4,762,709.

Taste-Masking

  • Martel, J., J. Tessler, P. Girault, and P. Grandadam., 1981. Acid type ion exchange resins and their use as medicines and compositions containing them. Patent EP 27,768.
  • Quinlan, J. M., 1980. Diethylcarbamazine resinate and Strylpyridinium resinate-diethylcarbamazine resinate edible anthelmintic tablets for companion animals. Patent GB 2,055,575.

 

Cholestyramine Application Reference List

  • Irwin, W. J, R. MacHale, and P. J. Watts (1990). Drug-delivery by ion exchange. Part VII: Release of acidic drugs from anionic exchange resinate complexes. Drug. Dev. Ind. Pharm. 16(6):883-898.
  • Sriwongjanya, Mongkol; Bodmeier, Roland; Effect of ion exchange resins on the drug release from matrix tablets; College Pharmacy, Freie Universitaet Berlin, Berlin, D-12169, Germany; Eur. J. Pharm. Biopharm. (1998), 46(3), 321-327.
  • Polli, Gerald P. and Shoop, Clyde E., (Merck and Co. USA), 1976. Palatable cholestyramine coacervate compositions. Patent US 3,974,272. Brauns H. A., Polli, Gerald P and Shoop, Clyde E., (Merck and Co., USA), 1974. Cholestyramine containing coacervate. Ger. Offen DE 2,344,090.
  • Kunin, Robert; Blood cholesterol reducing pharmaceutical composition; 1998; Patent US 5840339.